Ad
related to: when will pamrevlumab be approvedgoodrx.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Pamrevlumab (INN; [1] development code FG-3019) is a humanized monoclonal antibody designed for the treatment of idiopathic pulmonary fibrosis and pancreatic cancer. It binds to the connective tissue growth factor (CTGF) protein.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Tocilizumab was approved for the treatment of COVID‑19 in the European Union in December 2021, [15] and in the United States in December 2022. [ 32 ] In September 2021, Indian pharmaceutical firm Hetero obtained emergency use approval from the country's health authority, Drugs Controller General of India (DCGI), to produce a generic version ...
Winrevair was approved to treat pulmonary arterial hypertension (PAH), a progressive disorder caused by a constriction of arteries in the lungs, leading to symptoms such as shortness of breath ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The drug was approved as an add-on treatment to diet to reduce triglycerides in adults with the condition. The disorder affects fewer than 5,000 people in the U.S., according to government data ...
Mavrilimumab is a human monoclonal antibody [1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R). [2]Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc. [1] as an investigational drug for the treatment of rheumatoid arthritis
Ravulizumab was approved by the US Food and Drug Administration (FDA) in December 2018. [12] In April 2019, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the granting of a conditional marketing authorization for ravulizumab. [13] Ravulizumab was approved for medical use in the EU in ...
Ad
related to: when will pamrevlumab be approvedgoodrx.com has been visited by 100K+ users in the past month